JP2025533334A5 - - Google Patents

Info

Publication number
JP2025533334A5
JP2025533334A5 JP2025518537A JP2025518537A JP2025533334A5 JP 2025533334 A5 JP2025533334 A5 JP 2025533334A5 JP 2025518537 A JP2025518537 A JP 2025518537A JP 2025518537 A JP2025518537 A JP 2025518537A JP 2025533334 A5 JP2025533334 A5 JP 2025533334A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
patient
sotrasib
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025518537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025533334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053130 external-priority patent/WO2024072437A1/en
Publication of JP2025533334A publication Critical patent/JP2025533334A/ja
Publication of JP2025533334A5 publication Critical patent/JP2025533334A5/ja
Pending legal-status Critical Current

Links

JP2025518537A 2022-09-30 2022-12-16 ソトラシブ投与レジメン Pending JP2025533334A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263411789P 2022-09-30 2022-09-30
US63/411,789 2022-09-30
PCT/US2022/053130 WO2024072437A1 (en) 2022-09-30 2022-12-16 Sotorasib dosing regimen

Publications (2)

Publication Number Publication Date
JP2025533334A JP2025533334A (ja) 2025-10-06
JP2025533334A5 true JP2025533334A5 (cg-RX-API-DMAC10.html) 2026-01-28

Family

ID=85158814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025518537A Pending JP2025533334A (ja) 2022-09-30 2022-12-16 ソトラシブ投与レジメン

Country Status (9)

Country Link
US (2) US20260083741A1 (cg-RX-API-DMAC10.html)
EP (1) EP4593837A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025533334A (cg-RX-API-DMAC10.html)
KR (1) KR20250079183A (cg-RX-API-DMAC10.html)
AU (1) AU2022479909A1 (cg-RX-API-DMAC10.html)
JO (1) JOP20250064A1 (cg-RX-API-DMAC10.html)
MX (1) MX2025003741A (cg-RX-API-DMAC10.html)
TW (1) TW202415380A (cg-RX-API-DMAC10.html)
WO (1) WO2024072437A1 (cg-RX-API-DMAC10.html)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013557A (es) * 2021-05-18 2023-11-29 Amgen Inc Pauta posologica de sotorasib.

Similar Documents

Publication Publication Date Title
JP2024526145A5 (cg-RX-API-DMAC10.html)
JP2022022264A5 (cg-RX-API-DMAC10.html)
JP2023513015A5 (cg-RX-API-DMAC10.html)
JP2022533578A5 (cg-RX-API-DMAC10.html)
JP2022519375A5 (cg-RX-API-DMAC10.html)
JP2021513536A5 (cg-RX-API-DMAC10.html)
JP2016528162A5 (cg-RX-API-DMAC10.html)
JP2018505193A5 (cg-RX-API-DMAC10.html)
JP2011144190A (ja) 抗癌剤の効果増強剤
EA037152B1 (ru) Способ лечения рака
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2024527109A5 (cg-RX-API-DMAC10.html)
CN110198716A (zh) 癌症治疗
JP2014512355A5 (cg-RX-API-DMAC10.html)
JP2022526159A5 (cg-RX-API-DMAC10.html)
JP2025516558A5 (cg-RX-API-DMAC10.html)
JP2023524789A5 (cg-RX-API-DMAC10.html)
TW201625243A (zh) 用於治療黑素瘤之藥物組合
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2024518712A5 (cg-RX-API-DMAC10.html)
JP2023517671A5 (cg-RX-API-DMAC10.html)
CN121218987A (zh) 雌激素受体降解剂和akt抑制剂的组合
IL299028A (en) Methods and compositions for treating chemotherapy-induced diarrhea
JP2024517788A5 (cg-RX-API-DMAC10.html)